Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series

Paiella S.a · Marchegiani G.a · Miotto M.a · Malpaga A.a · Impellizzeri H.a · Montagnini G.a · Pollini T.a · Nessi C.a · Butturini G.b · Capelli P.c · Posenato I.c · Scarpa A.c, d · D'Onofrio M.e · De Robertis R.e · Cingarlini S.f · Boninsegna L.g · Bassi C.a · Salvia R.a · Landoni L.a

Author affiliations

aGeneral and Pancreatic Surgery Department, Pancreas Institute, University and Hospital Trust of Verona, Verona, bHepato-Pancreato-Biliary Surgery Unit, Casa di Cura Pederzoli, Peschiera del Garda, cDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, dARC-NET Research Center, University and Hospital Trust of Verona, and eDepartment of Radiology, Pancreas Institute, University and Hospital Trust of Verona, Verona, fDepartment of Radiology, Casa di Cura Pederzoli, Peschiera del Garda, gDepartment of Oncology, Pancreas Institute, University and Hospital Trust of Verona, Verona, and hDepartment of Surgery, Sacro Cuore Hospital, Negrar, Italy

Related Articles for ""

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 12, 2016
Accepted: May 26, 2017
Published online: June 07, 2017

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Abstract

Introduction: Cystic pancreatic neuroendocrine tumors (CPanNETs) represent an uncommon variant of pancreatic neuroendocrine tumors (PanNETs). Due to their rarity, there is a lack of knowledge with regard to clinical features and postoperative outcome. Methods: The prospectively maintained surgical database of a high-volume institution was queried, and 46 resected CPanNETs were detected from 1988 to 2015. Clinical, demographic, and pathological features and survival outcomes of CPanNETs were described and matched with a population of 92 solid PanNETs (SPanNETs) for comparison. Results: CPanNETs accounted for 7.8% of the overall number of resected PanNETs (46/587). CPanNETs were mostly sporadic (n = 42, 91%) and nonfunctioning (39%). Two functioning CPanNETs were detected (4.3%), and they were 2 gastrinomas. The median tumor diameter was 30 mm (range 10-120). All tumors were well differentiated, with 38 (82.6%) G1 and 8 (17.4%) G2 tumors. Overall, no CPanNET showed a Ki-67 >5%. A correct preoperative diagnosis of a CPanNET was made in half of the cases. After a median follow-up of >70 months, the 5- and 10-year overall survival of resected CPanNETs was 93.8 and 62.5%, respectively, compared to 92.7 and 84.6% for SPanNETs (p > 0.05). The 5- and 10-year disease-free survival rates were 94.5 and 88.2% for CPanNETs and 81.8 and 78.9% for SPanNETs, respectively (p > 0.05). Conclusion: In the setting of a surgical cohort, CPanNETs are rare, nonfunctional, and well-differentiated neoplasms. After surgical resection, they share the excellent outcome of their well-differentiated solid counterparts for both survival and recurrence.

© 2017 S. Karger AG, Basel


References

  1. Yang M, Zeng L, Zhang Y, Wang WG, Wang L, Ke NW, Liu XB, Tian BL: TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. Medicine (Baltimore) 2015;94:e660.
  2. Konukiewitz B, Enosawa T, Kloppel G: Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis. Virchows Arch 2011;458:47-53.
  3. Singhi AD, Chu LC, Tatsas AD, Shi C, Ellison TA, Fishman EK, Kawamoto S, Schulick RD, Wolfgang CL, Hruban RH, Edil BH: Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol 2012;36:1666-1673.
  4. Kongkam P, Al-Haddad M, Attasaranya S, O'Neil J, Pais S, Sherman S, DeWitt J: EUS and clinical characteristics of cystic pancreatic neuroendocrine tumors. Endoscopy 2008;40:602-605.
  5. Boninsegna L, Partelli S, D'Innocenzio MM, Capelli P, Scarpa A, Bassi C, Pederzoli P, Falconi M: Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 2010;92:246-251.
  6. Gaujoux S, Tang L, Klimstra D, Gonen M, Brennan MF, D'Angelica M, DeMatteo R, Fong Y, Jarnagin W, Allen PJ: The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis. Surgery 2012;151:518-525.
  7. Ahrendt SA, Komorowski RA, Demeure MJ, Wilson SD, Pitt HA: Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg 2002;6:66-74.
  8. Kamisawa T, Fukayama M, Koike M, Tabata I, Okamoto A: A case of malignant cystic endocrine tumor of the pancreas. Am J Gastroenterol 1987;82:86-89.
  9. Iacono C, Serio G, Fugazzola C, Zamboni G, Bergamo Andreis IA, Jannucci A, Zicari M, Dagradi A: Cystic islet cell tumors of the pancreas. A clinico-pathological report of two nonfunctioning cases and review of the literature. Int J Pancreatol 1992;11:199-208.
  10. Bordeianou L, Vagefi PA, Sahani D, Deshpande V, Rakhlin E, Warshaw AL, Fernandez-del Castillo C: Cystic pancreatic endocrine neoplasms: a distinct tumor type? J Am Coll Surg 2008;206:1154-1158.
  11. Goh BK, Ooi LL, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK: Clinico-pathological features of cystic pancreatic endocrine neoplasms and a comparison with their solid counterparts. Eur J Surg Oncol 2006;32:553-556.
  12. Ligneau B, Lombard-Bohas C, Partensky C, Valette PJ, Calender A, Dumortier J, Gouysse G, Boulez J, Napoleon B, Berger F, Chayvialle JA, Scoazec JY: Cystic endocrine tumors of the pancreas: clinical, radiologic, and histopathologic features in 13 cases. Am J Surg Pathol 2001;25:752-760.
  13. Schwartz RW, Munfakh NA, Zweng TN, Strodel WE, Lee E, Thompson NW: Nonfunctioning cystic neuroendocrine neoplasms of the pancreas. Surgery 1994;115:645-649.
  14. Koh YX, Chok AY, Zheng HL, Tan CS, Goh BK: A systematic review and meta-analysis of the clinicopathologic characteristics of cystic versus solid pancreatic neuroendocrine neoplasms. Surgery 2014;156:83-96.e82.
  15. Rindi G, Arnold R, Bosman FT, Bosman T, Carneiro F, Hruban R, Theise N, et al (eds): Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System, ed 4. Lyon, International Agency for Research on Cancer (IARC), 2010, pp 13-14.
  16. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162-166.
  17. Kawamoto S, Johnson PT, Shi C, Singhi AD, Hruban RH, Wolfgang CL, Edil BH, Fishman EK: Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. AJR Am J Roentgenol 2013;200:W283-W290.
  18. Figueiredo FA, Giovannini M, Monges G, Charfi S, Bories E, Pesenti C, Caillol F, Delpero JR: Pancreatic endocrine tumors: a large single-center experience. Pancreas 2009;38:936-940.
  19. Baker MS, Knuth JL, DeWitt J, LeBlanc J, Cramer H, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA: Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg 2008;12:450-456.
  20. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of Tumours of the Digestive System. WHO, Lyon, 2010.
  21. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23:824-833.
  22. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Kloppel G, Reed N, Kianmanesh R, Jensen RT, Vienna Consensus Conference participants: ENETS Consensus Guidelines Update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153-171.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 12, 2016
Accepted: May 26, 2017
Published online: June 07, 2017

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.